Viridian Therapeutics, Inc.
VRDN
$16.86
-$0.34-1.98%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 70.92M | 70.85M | 70.79M | 305.00K | 302.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 70.92M | 70.85M | 70.79M | 305.00K | 302.00K |
| Cost of Revenue | 337.39M | 336.68M | 315.93M | 298.83M | 268.40M |
| Gross Profit | -266.47M | -265.83M | -245.15M | -298.53M | -268.10M |
| SG&A Expenses | 116.89M | 95.31M | 77.23M | 67.31M | 63.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 460.12M | 437.74M | 398.91M | 371.89M | 337.31M |
| Operating Income | -389.20M | -366.90M | -328.12M | -371.59M | -337.01M |
| Income Before Tax | -360.59M | -342.60M | -301.97M | -344.06M | -308.32M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -360.59 | -342.60 | -301.97 | -344.06 | -308.32 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -360.59M | -342.60M | -301.97M | -344.06M | -308.32M |
| EBIT | -389.20M | -366.90M | -328.12M | -371.59M | -337.01M |
| EBITDA | -388.73M | -366.44M | -327.66M | -371.10M | -336.49M |
| EPS Basic | -3.32 | -3.29 | -3.02 | -3.56 | -3.33 |
| Normalized Basic EPS | -2.50 | -2.52 | -2.33 | -2.78 | -2.65 |
| EPS Diluted | -3.32 | -3.29 | -3.02 | -3.56 | -3.33 |
| Normalized Diluted EPS | -2.50 | -2.52 | -2.33 | -2.78 | -2.65 |
| Average Basic Shares Outstanding | 359.97M | 339.10M | 324.77M | 309.41M | 291.67M |
| Average Diluted Shares Outstanding | 359.97M | 339.10M | 324.77M | 309.41M | 291.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |